Bram ten Cate

Fas Receptor Clustering and Involvement of the Death Receptor Pathway in Rituximab-Mediated Apoptosis with Concomitant Sensitization of Lymphoma B Cells to Fas-Induced Apoptosis

Alja J. Stel, Bram ten Cate, S. Jacobs et al. · The Journal of Immunology · 2007 · 83 citations · Full text

Life Sciences, Cell Biology, Immunology +17

A novel AML-selective TRAIL fusion protein that is superior to Gemtuzumab Ozogamicin in terms of in vitro selectivity, activity and stability

Bram ten Cate, Edwin Bremer, Marco de Bruyn et al. · Leukemia · 2009 · 63 citations · Full text

Pharmacy, Medicinal Chemistry, Molecular Biology +7

Selective induction of apoptosis in leukemic B-lymphoid cells by a CD19-specific TRAIL fusion protein

Julia Stieglmaier, Edwin Bremer, Christian Kellner et al. · Cancer Immunology Immunotherapy · 2007 · 62 citations · Full text

Life Sciences, Cancer Biology, Oncology +16

CD7-restricted activation of Fas-mediated apoptosis: a novel therapeutic approach for acute T-cell leukemia

Edwin Bremer, Bram ten Cate, Douwe F. Samplonius et al. · Blood · 2005 · 55 citations · Full text

Life Sciences, Immunology, Oncology +17

The histone deacetylase inhibitor valproic acid potently augments gemtuzumab ozogamicin-induced apoptosis in acute myeloid leukemic cells

Bram ten Cate, Douwe F. Samplonius, Theo Bijma et al. · Leukemia · 2006 · 48 citations · Full text

Medicine, Oncology, Pharmacology +16